COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01938196
Recruitment Status : Completed
First Posted : September 10, 2013
Last Update Posted : November 13, 2014
Information provided by (Responsible Party):
Kissei Pharmaceutical Co., Ltd.

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of titrated KWA-0711 dose in chronic constipation patients.

Condition or disease Intervention/treatment Phase
Chronic Constipation Drug: KWA-0711 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Primary Completion Date : January 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Constipation

Arm Intervention/treatment
Experimental: KWA-0711 Dose1 Drug: KWA-0711
Experimental: KWA-0711 Dose2 Drug: KWA-0711
Experimental: KWA-0711 Dose3 Drug: KWA-0711
Experimental: KWA-0711 Dose4 Drug: KWA-0711
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Improvement of signs and symptoms associated with constipation [ Time Frame: 5 weeks ]
    • Frequency of Spontaneous Bowel Movements
    • Bowel Movement Timing
    • Stool Consistency
    • Abdominal Assessment
    • QOL Assessment

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • The patients who experienced fewer than three spontaneous bowel movements per week for more than 6 months prior to the enrollment.
  • The patients who experienced one or more of the following signs or symptoms during more than 25% of bowel movements for more than 6 months: straining, lumpy or hard stools, and a sensation of incomplete evacuation

Exclusion Criteria:

  • Patients who have secondary constipation caused by systemic disorder.
  • Patients who have organic constipation.
  • Patients who received intestinal resection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01938196

Layout table for location information
Tokyo, Japan
Sponsors and Collaborators
Kissei Pharmaceutical Co., Ltd.
Layout table for additonal information
Responsible Party: Kissei Pharmaceutical Co., Ltd. Identifier: NCT01938196    
Other Study ID Numbers: KWA1202
First Posted: September 10, 2013    Key Record Dates
Last Update Posted: November 13, 2014
Last Verified: November 2014
Keywords provided by Kissei Pharmaceutical Co., Ltd.:
Chronic Constipation
Functional gastrointestinal disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Signs and Symptoms, Digestive
Signs and Symptoms